France· FR:61420887

VYNDAQEL 61 mg, capsule molle

A tafamidis product containing tafamidis, registered in France by PFIZER EUROPE MA EEIG (BELGIQUE), on the national reimbursement list. The same ATC class is registered in 17 of our 19 countries.

Reimbursed in France (Assurance maladie)ATC N07XX08

Checked against Base de données publique des médicaments — BDPM (France) on September 12, 2026

Informational only — not a medical device.

Compare price across countriesPer daily dose · free account Ask the assistant about tafamidisAnswers with sources · free account Check interactionsSeverity free · mechanism on Growth

Where it is registered

Tafamidis is registered in 17 of 19 countries.

Countries holding a registration under ATC N07XX08 (tafamidis), each read from that country’s own register.

This record: France, from Base de données publique des médicaments — BDPM (France)
9 of them publish a price we can compare per daily dose

Search tafamidis products by name

Tafamidis · ATC N07XX08

17 / 19 countries

Belgiumprice
Canada
Czechiaprice
Denmark
Finlandprice
Franceprice
Germany
Icelandprice
Ireland
Japan
Netherlands
Norwayprice
Polandprice
Sweden
Switzerlandprice
United Kingdom
United Statesprice

Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of tafamidis costs, country by country.

Normalised to the WHO defined daily dose (20 mg), the median price runs from $0.082 in France to $118.78 in Switzerland — a ×1457 gap.

France: $0.082 per daily dose (median across products in the class)
Public list prices, converted to USD at the rate date shown

Open the full comparison — free account Drug prices for market access

Tafamidis · price per daily dose (20 mg)

USD · FX 28 Sept 2026

CH Switzerland$118.78
FR France$0.082

Median listed price per WHO defined daily dose, in each market that publishes a price. Open the full comparison

The record

At a glance

Base de données publique des médicaments — BDPM (France)

Active substance: TAFAMIDIS
Manufacturer: PFIZER EUROPE MA EEIG (BELGIQUE)
Country: France (FR)
ATC code: N07XX08
ATC class: Tafamidis
Defined daily dose: 20 mg, O
Reimbursed: Yes
Source register: Base de données publique des médicaments — BDPM (France)
Last checked: September 12, 2026

Packs & prices · 1

1 priced

cip13
3400930202074
plaquettes PVC polyamide aluminium PVC-Aluminium de 30 x 1 capsules (conditionnement unitaire)
EUR 6.55

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

18 interactions on record for tafamidis.

Graded by severity as the source publishes them — 2 severe. Severity grades are free for everyone; mechanism and management come with Growth.

Severity for every pair — free, no plan needed
The source, licence and sync date on every record
Mechanism and what to do for each pair — Growth plan

Check tafamidis against other medicines How interaction checks work

Tafamidis · interactions on record

18 records

2 severe
16 moderate

Most severe, free to view

OzanimodL04AA38severe
OzanimodL04AE02severe
EltrombopagB02BX05moderate
LusutrombopagB02BX07moderate

Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.

Mechanism and what to do, in the interaction check

Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Tafamidis in 15 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All tafamidis products

Authorised across Europe · EMA

The same active substance is authorised in 10 EEA countries. Names it is sold under:

Austria · Tafamidis Stada, Tafamidis Viatris
Belgium · Tafamidis Viatris
Germany · Tafamidis Al, Tafamidis Viatris
Spain · Tafamidis Stada, Tafamidis Viatris
United Kingdom (Northern Ireland) · Tafamidis Thornton & Ross
Iceland · Vyndaqel
Liechtenstein · Vyndaqel
Norway · Tafamidis Stada Nordic, Tafamidis Viatris
Sweden · Tafamidis Stada Nordic, Tafamidis Viatris
Slovenia · Tafamidis Sumar

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Base de données publique des médicaments — BDPM (France). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload

GET /v1/drugs/04a2aa69-99ba-4d7c-977e-f50c08b2c7c9
GET /v1/drugs/04a2aa69-99ba-4d7c-977e-f50c08b2c7c9?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "cis": "61420887",
  "date_amm": "2020-02-17",
  "type_amm": "Procédure centralisée",
  "numero_ue": "EU/1/11/717",
  "substance": "TAFAMIDIS",
  "atc_source": "fr_atc_restore_2026-09-06",
  "statut_amm": "Autorisation active",
  "statut_bdm": null,
  "forme_pharmaceutique": "capsule molle",
  "voies_administration": "orale",
  "etat_commercialisation": "Commercialisée",
  "surveillance_renforcee": "Oui"
}

API reference MCP server Plans

See everything about tafamidis.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it free Open in the console